60
Participants
Start Date
December 11, 2020
Primary Completion Date
October 16, 2024
Study Completion Date
April 22, 2025
AMG 714
anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
Placebo
Placebo for AMG 714
nbUVB phototherapy
Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
Northwell Health, Lake Success
Perelman School of Medicine, University of Pennsylvania: Department of Dermatology, Philadelphia
Henry Ford Health System, Detroit
University of California, Irvine: Department of Dermatology, Irvine
University of California Davis Health System: Department of Dermatology, Sacramento
Yale University School of Medicine: Department of Dermatology, New Haven
Tufts Medical Center: Department of Dermatology, Boston
University of Massachusetts Medical School, Worcester
Collaborators (2)
Immune Tolerance Network (ITN)
NETWORK
PPD Development, LP
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
Amgen
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH